Clearmind Medicine Announces New Patent Application for Ibogaine Therapy
Clearmind Medicine Inc. (NASDAQ: CMND), a prominent clinical-stage biotech company recognized for creating innovative therapeutics derived from psychedelics, has exciting news. They've filed an international patent application under the Patent Cooperation Treaty (PCT) for a groundbreaking combination therapy utilizing Ibogaine and N-Acylethanolamines.
The Promise of Ibogaine in Addiction Treatment
Ibogaine, a potent compound extracted from the Tabernanthe iboga plant, has shown remarkable promise in clinical trials targeting various substance use disorders, including opioid use disorder (OUD) and cocaine use disorder (CUD). As ongoing research continues to affirm its effectiveness, Ibogaine is emerging as a potential anti-addiction agent, opening doors for new treatment avenues that could greatly benefit those struggling with addiction.
Partnership with SciSparc Ltd.
This significant development stems from a fruitful collaboration between Clearmind and SciSparc Ltd. (NASDAQ: SPRC), a pharmaceutical company specializing in central nervous system disorders. Together, they are working to create innovative therapies that blend psychedelic compounds with the advantageous qualities of N-Acylethanolamines, such as Palmitoylethanolamide (PEA).
Cutting-Edge Solutions for Mental Health
Dr. Adi Zuloff-Shani, CEO of Clearmind, highlighted the company’s commitment to pioneering breakthroughs in the psychedelic therapy space. He remarked, “This patent publication demonstrates Clearmind's determination to build a comprehensive patent portfolio filled with groundbreaking technologies. Our aim is to provide safe and effective treatments for mental health challenges that continue to be overlooked. Although Ibogaine treatments have generally shown safety under medical supervision, concerns persist regarding adverse effects from raw iboga plant material. By combining Ibogaine with PEA, we hope to enhance safety and efficacy, thereby improving the therapeutic outcomes for our patients.”
About Clearmind Medicine Inc.
Clearmind Medicine is at the forefront of the psychedelic pharmaceutical field, focusing on researching and developing unique compounds derived from psychedelics to address pressing health issues, including alcohol use disorder. With a clear vision for the future, Clearmind aims to transform these psychedelic compounds into regulated medicines that can bring meaningful benefits to large populations.
Broadening the Intellectual Property Portfolio
The company boasts an impressive portfolio featuring nineteen patent families and a total of thirty granted patents. Clearmind is dedicated to pursuing further patent protections for its innovations and is well-positioned to acquire additional intellectual property as opportunities present themselves.
About SciSparc Ltd.
SciSparc Ltd. is well-known for its commitment to developing advanced cannabinoid pharmaceuticals. The company spearheads initiatives related to drug programs designed to treat various conditions, including Tourette Syndrome and Alzheimer's, underscoring its mission to tackle a wide range of health challenges through scientific advancements.
Contact Information for Investor Relations
For more details about Clearmind Medicine, interested parties can visit the company’s official website or reach out directly: Investors: invest@clearmindmedicine.com | Telephone: (604) 260-1566. For general inquiries, please contact Info@Clearmindmedicine.com.
Frequently Asked Questions
What does Clearmind Medicine aim to achieve?
Clearmind Medicine specializes in discovering and developing psychedelic-derived therapeutics designed to address serious mental health issues.
What is Ibogaine and its role in therapy?
Ibogaine is a compound obtained from the iboga plant, and it's being explored for its potential in treating substance use disorders through novel therapies.
Which company partnered with Clearmind in this new therapy development?
Clearmind has partnered with SciSparc Ltd. to innovate combination therapies that bolster the effects of psychedelics in mental health treatment.
What benefits might Clearmind’s new therapy offer?
This therapy could enhance safety and effectiveness for patients facing addiction challenges, significantly improving treatment outcomes.
How can I keep track of Clearmind Medicine's progress?
You can stay updated by visiting Clearmind's official website or subscribing to their investor relations updates.